Article

New marker may be more specific for prostate cancer

Researchers at Johns Hopkins have made significant progress on the development of a new serum biomarker known as Early Prostate Cancer Antigen-2.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Vikram Narayran, MD, on tech-driven changes that are enhancing patient care
Vikram Narayran, MD, on tech-driven changes that are enhancing patient care
Justin Dubin, MD, on leveraging digital tools to improve patient buy-in
Justin Dubin, MD, on leveraging digital tools to improve patient buy-in
1 expert is featured in this series.
Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
1 expert is featured in this series.
Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
DNA helix | Image Credit: © Radomir Jovanovic - stock.adobe.com
Betty Wang, MD, and Laura Bukavina, MD, MPH, MSc, discuss ctDNA's role in NMIBC treatment decisions
Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
The Growing Call for Combination Therapy in NMIBC Treatment
The Growing Call for Combination Therapy in NMIBC Treatment
Optimizing NMIBC Treatment Through Sequencing and Patient Preference
Optimizing NMIBC Treatment Through Sequencing and Patient Preference
Mina Fam, MD, on managing expectations around testosterone replacement therapy
Mina Fam, MD, on managing expectations around testosterone replacement therapy
Justin Dubin, MD, on the role for AI in patient education
Justin Dubin, MD, on the role for AI in patient education
Related Content
CMS issues reimbursement code for PSMA-PET imaging agent Gozellix
July 15th 2025

CMS issues reimbursement code for PSMA-PET imaging agent Gozellix

Hannah Clarke
The level II code A9616 will be effective starting on October 1, 2025.
Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD
July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD
Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
Study shows favorable outcomes with guideline-based treatment for localized prostate cancer
July 14th 2025

Study shows favorable outcomes with guideline-based treatment for localized prostate cancer

Hannah Clarke
“Our data support adherence to guideline recommendations for treatment of prostate cancer,” says Pietro Scilipoti, MD.
Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD
Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
Patient talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke
“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.
Data supports combination intravesical chemotherapy for high-risk NMIBC
July 10th 2025

Data supports combination intravesical chemotherapy for high-risk NMIBC

Hannah Clarke
“This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.
© 2025 MJH Life Sciences

All rights reserved.